IFP Advisors Inc Buys Shares of 2,250 Tempus AI, Inc. (NASDAQ:TEM)

IFP Advisors Inc bought a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,250 shares of the company’s stock, valued at approximately $76,000.

A number of other institutional investors also recently made changes to their positions in TEM. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC acquired a new position in Tempus AI in the fourth quarter worth $67,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Tempus AI during the fourth quarter valued at $178,000. Stifel Financial Corp bought a new stake in Tempus AI during the third quarter valued at $218,000. Finally, James J. Burns & Company LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth $236,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TEM. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Piper Sandler dropped their price target on Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research report on Tuesday. Needham & Company LLC boosted their price objective on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. cut Tempus AI from an “overweight” rating to a “neutral” rating and raised their target price for the company from $50.00 to $55.00 in a research note on Tuesday, February 25th. Finally, TD Cowen restated a “buy” rating and set a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.73.

Insiders Place Their Bets

In other news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. The trade was a 2.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the sale, the chief executive officer now owns 4,895,589 shares in the company, valued at $287,615,853.75. The trade was a 39.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,823,701 shares of company stock worth $320,906,059 over the last ninety days.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $53.06 on Thursday. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a 50 day moving average of $53.38 and a 200-day moving average of $52.56.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.